Denise Faltischek Buys 2,500 Shares of Tilray Brands (NASDAQ:TLRY) Stock

Tilray Brands, Inc. (NASDAQ:TLRY) insider Denise Faltischek purchased 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average price of $4.78 per share, for a total transaction of $11,950.00. Following the purchase, the insider owned 141,285 shares in the company, valued at $675,342.30. The trade was a 1.80% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Tilray Brands Stock Performance

TLRY stock traded down $0.09 during mid-day trading on Tuesday, hitting $4.55. 4,007,056 shares of the company were exchanged, compared to its average volume of 4,323,631. The business has a 50 day simple moving average of $4.66 and a 200-day simple moving average of $6.20. The company has a current ratio of 2.21, a quick ratio of 1.37 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $530.89 million, a PE ratio of -4.20 and a beta of 1.90. Tilray Brands, Inc. has a 1-year low of $3.67 and a 1-year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Tuesday, July 28th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 13.11% and a negative return on equity of 7.76%. The firm had revenue of $281.71 million during the quarter, compared to analyst estimates of $246.30 million. On average, equities analysts forecast that Tilray Brands, Inc. will post -0.34 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TLRY shares. TD Cowen dropped their target price on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Wall Street Zen lowered shares of Tilray Brands from a “hold” rating to a “sell” rating in a research report on Saturday. TD Securities upgraded shares of Tilray Brands to a “strong-buy” rating in a research note on Friday. Finally, Weiss Ratings downgraded shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Hedge Funds Weigh In On Tilray Brands

A number of hedge funds have recently added to or reduced their stakes in TLRY. AQR Capital Management LLC lifted its position in shares of Tilray Brands by 1,839.7% during the 1st quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock valued at $399,000 after acquiring an additional 575,757 shares during the period. XTX Topco Ltd acquired a new position in Tilray Brands in the second quarter valued at about $112,000. Cerity Partners LLC raised its stake in Tilray Brands by 98.5% in the second quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after purchasing an additional 45,929 shares in the last quarter. Ausdal Financial Partners Inc. bought a new stake in Tilray Brands during the second quarter worth about $939,000. Finally, Bank of America Corp DE grew its stake in Tilray Brands by 26.5% during the second quarter. Bank of America Corp DE now owns 311,810 shares of the company’s stock worth $129,000 after buying an additional 65,379 shares in the last quarter. Institutional investors own 9.35% of the company’s stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.